IR-Center Handelsblatt
Unternehmenssuche:

SphingoTec GmbH

News Detail

DGAP-News News vom 06.08.2020

SphingoTec to Present at the Solebury Trout's Summer Private Company Showcase

DGAP-News: SphingoTec GmbH / Key word(s): Conference
06.08.2020 / 13:13
The issuer is solely responsible for the content of this announcement.

Hennigsdorf/Berlin, Germany - August 6, 2020 - Diagnostics company SphingoTec GmbH ("SphingoTec") today announced that Dr Andreas Bergman, CEO, and Ferdinand Von Humboldt, CFO, will be presenting a corporate overview at the Summer Private Company Showcase, hosted by Solebury Trout on August 10, 2020.

SphingoTec develops and markets in-vitro diagnostic tests for novel and proprietary biomarkers in diagnostically underserved acute and critical care conditions to improve patient outcomes. The company makes its assays for real-time assessment of kidney function, endothelial function and cardiac depression available on its fully integrated Nexus IB10 point-of-care platform.


Presentation Details:
Date:               August 10, 2020
Time:               4:00 p.m. CEST

Please click the following link to register: https://troutaccess.com/index.php/c/Summer2020PCS


About SphingoTec
SphingoTec GmbH ( "SphingoTec"; Hennigsdorf near Berlin, Germany) develops and markets innovative in-vitro diagnostic (IVD) tests for novel and proprietary biomarkers for the diagnosis, prediction and monitoring of acute medical conditions, such as sepsis, acute heart failure, circulatory shock, and acute kidney injury in order to support patient management and provide guidance for treatment strategies. SphingoTec's proprietary biomarker portfolio includes Bioactive Adrenomedullin(bio-ADM(R)), a unique biomarker for real-time assessment of endothelial function in conditions like sepsis or congestive heart failure, Proenkephalin (penKid(R)), a unique biomarker for real-time assessment of kidney function, and Dipeptidyl Peptidase 3 (DPP3), a unique biomarker for cardiac depression. IVD tests for SphingoTec's proprietary biomarkers are made available as sphingotest(R) microtiterplate tests as well as point-of-care tests on the Nexus IB10 immunoassay platform by SphingoTec's subsidiary Nexus Dx Inc. (San Diego, CA, USA) alongside a broad menu of established and commonly used tests for acute and critical care.

For more information please visit our website: https://sphingotec.com/

Contact:
SphingoTec GmbH
Ferdinand von Humboldt
CFO
+ 49 330 220 56 50
[email protected]
 


06.08.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


show this